Ghrelin and neurohumoral antagonists in the treatment of Cachexia associated with cardiopulmonary disease

Internal Medicine

Volumn 45, Issue 13, 2006, Pages 837-

  Lainscak, Mitja ^a,b   Andreas, Stefan ^c   Scanlon, Paul D ^d   Somers, Virend K ^d   Anker, Stefan D ^a,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b General Hospital Murska Sobota   (Slovenia)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d MAYO CLINIC   (United States)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Cachexia; Chronic heart failure; Chronic obstructive pulmonary disease; Ghrelin; Neurohumoral antagonists

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GHRELIN; HORMONE ANTAGONIST; NEUROHORMONE; NEUROHORMONE ANTAGONIST; UNCLASSIFIED DRUG;

BODY COMPOSITION; CACHEXIA; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; FUNCTIONAL STATUS; HEART DISEASE; HEART FAILURE; HUMAN; LETTER; LUNG DISEASE; MUSCLE ATROPHY; PATHOPHYSIOLOGY; PROGNOSIS;

CACHEXIA; HEART FAILURE, CONGESTIVE; HUMANS; PEPTIDE HORMONES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33746879963     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.45.1867     Document Type: Letter

References (5)

1. Nagaya N, Kojima M, Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia. Intern Med 45: 127-134, 2006.
2. John M, Hoernig S, Doehner W, Okonko DD, Witt C, Anker SD. Anemia and inflammation in COPD. Chest 127: 825-829, 2005
3. Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic activation of chronic lung disease. Chest 128: 3618-3624, 2005.
4. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361: 1077-1083, 2003.
5. Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study. Int J Cardiol 106: 319-322, 2006.